ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » New Jersey » Rheumatology

Top Rheumatology Prescribers in New Jersey

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
CIRO CARAFA MD

Rheumatology

11,521

$654K

496
442 are 65+

7%
patients receiving schedule two controlled substances

Avg: 5%

8%
patients receiving schedule three controlled substances

Avg: 6%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

25%
prescriptions for brand name drugs

Avg: 31%

$57
Average prescription price

Avg: $197

ROBERT FOGARI MD

Rheumatology

11,125

$1.69M

692
490 are 65+

2%
patients receiving schedule two controlled substances

Avg: 5%

3%
patients receiving schedule three controlled substances

Avg: 6%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

41%
prescriptions for brand name drugs

Avg: 31%

$152
Average prescription price

Avg: $197

DOMINIC MAIELLO MD

Rheumatology

6,185

$2.23M

402
280 are 65+

0%
patients receiving schedule two controlled substances

Avg: 5%

17%
patients receiving schedule three controlled substances

Avg: 6%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

39%
prescriptions for brand name drugs

Avg: 31%

$361
Average prescription price

Avg: $197

FREDERICK BRANDT

Rheumatology

5,567

$1.37M

554
440 are 65+

5%
patients receiving schedule two controlled substances

Avg: 5%

13%
patients receiving schedule three controlled substances

Avg: 6%

8%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

33%
prescriptions for brand name drugs

Avg: 31%

$247
Average prescription price

Avg: $197

STEPHEN SOLOWAY M.D.,FACP.,FACR.,CCD

Rheumatology

5,049

$877K

653
381 are 65+

10%
patients receiving schedule two controlled substances

Avg: 5%

12%
patients receiving schedule three controlled substances

Avg: 6%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

23%
prescriptions for brand name drugs

Avg: 31%

$174
Average prescription price

Avg: $197

BERNARD SACCARO MD

Rheumatology

4,729

$541K

296
252 are 65+

0%
patients receiving schedule two controlled substances

Avg: 5%

0%
patients receiving schedule three controlled substances

Avg: 6%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

31%
prescriptions for brand name drugs

Avg: 31%

$114
Average prescription price

Avg: $197

SCOTT BEEDE MD

Rheumatology

4,666

$750K

386
285 are 65+

17%
patients receiving schedule two controlled substances

Avg: 5%

14%
patients receiving schedule three controlled substances

Avg: 6%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 31%

$161
Average prescription price

Avg: $197

ANIL KAPOOR MD

Rheumatology

4,592

$471K

303
198 are 65+

19%
patients receiving schedule two controlled substances

Avg: 5%

20%
patients receiving schedule three controlled substances

Avg: 6%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 31%

$103
Average prescription price

Avg: $197

DAVID WANALISTA D.O.

Rheumatology

4,486

$864K

515
389 are 65+

21%
patients receiving schedule two controlled substances

Avg: 5%

10%
patients receiving schedule three controlled substances

Avg: 6%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

33%
prescriptions for brand name drugs

Avg: 31%

$193
Average prescription price

Avg: $197

JANET KROMMES M.D.

Rheumatology

4,309

$1.35M

471
387 are 65+

15%
patients receiving schedule two controlled substances

Avg: 5%

18%
patients receiving schedule three controlled substances

Avg: 6%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

30%
prescriptions for brand name drugs

Avg: 31%

$314
Average prescription price

Avg: $197

NICHOLAS SCARPA M.D.

Rheumatology

4,237

$1.18M

466
384 are 65+

0%
patients receiving schedule two controlled substances

Avg: 5%

0%
patients receiving schedule three controlled substances

Avg: 6%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

42%
prescriptions for brand name drugs

Avg: 31%

$279
Average prescription price

Avg: $197

JEANNE PARE M.D.

Rheumatology

4,202

$597K

406
316 are 65+

8%
patients receiving schedule two controlled substances

Avg: 5%

21%
patients receiving schedule three controlled substances

Avg: 6%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

30%
prescriptions for brand name drugs

Avg: 31%

$142
Average prescription price

Avg: $197

LEONARD GROSSMAN M.D.

Rheumatology

4,193

$385K

471
439 are 65+

5%
patients receiving schedule two controlled substances

Avg: 5%

5%
patients receiving schedule three controlled substances

Avg: 6%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

31%
prescriptions for brand name drugs

Avg: 31%

$92
Average prescription price

Avg: $197

DAVID SAGRANSKY M.D.

Rheumatology

4,082

$1.15M

506
458 are 65+

4%
patients receiving schedule two controlled substances

Avg: 5%

4%
patients receiving schedule three controlled substances

Avg: 6%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

33%
prescriptions for brand name drugs

Avg: 31%

$282
Average prescription price

Avg: $197

STEVEN GOLOMBEK M.D.

Rheumatology

4,064

$535K

567
450 are 65+

4%
patients receiving schedule two controlled substances

Avg: 5%

7%
patients receiving schedule three controlled substances

Avg: 6%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

32%
prescriptions for brand name drugs

Avg: 31%

$132
Average prescription price

Avg: $197

RICHARD ANDRON MD

Rheumatology

3,974

$442K

354
303 are 65+

4%
patients receiving schedule two controlled substances

Avg: 5%

5%
patients receiving schedule three controlled substances

Avg: 6%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

32%
prescriptions for brand name drugs

Avg: 31%

$111
Average prescription price

Avg: $197

ALAN ZALKOWITZ M.D.

Rheumatology

3,931

$462K

327
302 are 65+

0%
patients receiving schedule two controlled substances

Avg: 5%

0%
patients receiving schedule three controlled substances

Avg: 6%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

36%
prescriptions for brand name drugs

Avg: 31%

$117
Average prescription price

Avg: $197

THOMAS NUCATOLA MD

Rheumatology

3,818

$559K

378
316 are 65+

7%
patients receiving schedule two controlled substances

Avg: 5%

8%
patients receiving schedule three controlled substances

Avg: 6%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

28%
prescriptions for brand name drugs

Avg: 31%

$146
Average prescription price

Avg: $197

GREGORY RIHACEK MD

Rheumatology

3,760

$1.22M

302
239 are 65+

16%
patients receiving schedule two controlled substances

Avg: 5%

10%
patients receiving schedule three controlled substances

Avg: 6%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

32%
prescriptions for brand name drugs

Avg: 31%

$323
Average prescription price

Avg: $197

WADIE TOMA MD

Rheumatology

3,730

$396K

432
315 are 65+

0%
patients receiving schedule two controlled substances

Avg: 5%

0%
patients receiving schedule three controlled substances

Avg: 6%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 31%

$106
Average prescription price

Avg: $197

MICHAEL GROSS MD

Rheumatology

3,729

$776K

359
292 are 65+

13%
patients receiving schedule two controlled substances

Avg: 5%

9%
patients receiving schedule three controlled substances

Avg: 6%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

35%
prescriptions for brand name drugs

Avg: 31%

$208
Average prescription price

Avg: $197

HARLEEN BRAR MD

Rheumatology

3,653

$433K

324
204 are 65+

15%
patients receiving schedule two controlled substances

Avg: 5%

7%
patients receiving schedule three controlled substances

Avg: 6%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

25%
prescriptions for brand name drugs

Avg: 31%

$119
Average prescription price

Avg: $197

GILBERT KEPECS MD

Rheumatology

3,535

$750K

373
312 are 65+

3%
patients receiving schedule two controlled substances

Avg: 5%

6%
patients receiving schedule three controlled substances

Avg: 6%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

26%
prescriptions for brand name drugs

Avg: 31%

$212
Average prescription price

Avg: $197

ROBERT SPEER D.O.

Rheumatology

3,508

$376K

233
197 are 65+

6%
patients receiving schedule two controlled substances

Avg: 5%

8%
patients receiving schedule three controlled substances

Avg: 6%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

30%
prescriptions for brand name drugs

Avg: 31%

$107
Average prescription price

Avg: $197

SHELDON SOLOMON M.D.

Rheumatology

3,318

$600K

513
453 are 65+

10%
patients receiving schedule two controlled substances

Avg: 5%

18%
patients receiving schedule three controlled substances

Avg: 6%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

33%
prescriptions for brand name drugs

Avg: 31%

$181
Average prescription price

Avg: $197

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank